Genedrive : Result of AGM

For release: 31 December 2018

genedrive plc ('genedrive' or the 'Company')

Result of AGM

genedrive plc (LSE: GDR), the near patient molecular diagnostics company, announces that at the Annual General Meeting, held today, all resolutions proposed were duly passed.

- Ends -

For further details please contact:

genedrive plc	[phone]
David Budd: CEO
Matthew Fowler: CFO
Peel Hunt LLP
James Steel	[phone]
Oliver Jackson
Stanford Capital Partners Limited	[phone]
Patrick Claridge
John Howes
Consilium Strategic Communications	[phone]
Chris Gardner	[e-mail]
Matthew Neal
Laura Thornton

Notes to Editors

About genedrive plc

genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Genedrive® HCV-ID test has received CE-IVD Certification and has been launched in Africa and Asia Pacific. genedrive has distribution agreements with subsidiaries of Sysmex Corporation for the distribution of the Genedrive® platform in the EMEA and SE Asia (ex-India), and with ARKRAY Healthcare pvt Ltd for the distribution of the Genedrive® HCV-ID Kit and Genedrive® platform in India. Further details can be found at: www.genedriveplc.com andwww.genedrive.com. The Company also has tests in development for tuberculosis (mTB) and Antibiotic Induced Hearing Loss (AIHL).